| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 137,816 | 147,585 | ||
| Prepaid expenses and other current assets | 1,632 | 2,261 | ||
| Total current assets | 139,448 | 149,846 | ||
| Restricted cash | 500 | 500 | ||
| Property and equipment, net | 2,029 | 2,308 | ||
| Operating right-of-use asset | 4,459 | 4,653 | ||
| Other assets | 570 | 570 | ||
| Total assets | 147,006 | 157,877 | ||
| Accounts payable | 2,059 | 1,671 | ||
| Accrued expenses and other current liabilities | 6,986 | 6,458 | ||
| Total current liabilities | 9,045 | 8,129 | ||
| Term loan,non-current | 20,314 | 20,122 | ||
| Convertible grant agreement | 2,124 | 2,000 | ||
| Lease liability, long-term | 3,966 | 4,214 | ||
| Total liabilities | 35,449 | 34,465 | ||
| Common stock (par value 0.0001), 500,000 shares authorized 27,168 and 26,987 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 3 | 3 | ||
| Additionalpaid-incapital | 296,992 | 294,649 | ||
| Accumulated deficit | -185,452 | -171,271 | ||
| Accumulated other comprehensive income (loss) | 14 | 31 | ||
| Total stockholders equity | 111,557 | 123,412 | ||
| Total liabilities and stockholders equity | 147,006 | 157,877 | ||
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)